Market Overview

Piper Jaffray Reiterates Underweight on Solazyme on Dissolution of Roquette JV

Related SZYM
UPDATE: Morgan Stanley Downgrades Solazyme On Lack Of Conviction In Long-Term Outcome
Mid-Morning Market Update: Markets Edge Lower; Humana Profit Misses Estimates

In a report published on Monday, Piper Jaffray analyst Mike J. Ritzenthaler reiterated an Underweight rating and a price target of $5 on Solazyme (NASDAQ: SZYM).

In the report, Piper Jaffray stated, "The history of the Industrial Biotechnology space is littered with major strategic partners pulling out of agreements that struggled during commercialization – when promise doesn't match up with reality. Now we can add Roquette to that list, even after Solazyme's most important partner in nutritional markets spent meaningfully to develop a sophisticated view on the commercial potential. We can presume that if profitability was as near at hand as Solazyme's management team would have us believe, Roquette's hat would still be in the ring."

Solazyme closed on Friday at $12.62.

Latest Ratings for SZYM

DateFirmActionFromTo
Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for SZYM
View the Latest Analyst Ratings

Posted-In: Mike J. Ritzenthaler Piper JaffrayAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SZYM)

Around the Web, We're Loving...

Get Benzinga's Newsletters